Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

Author's Avatar
May 18, 2020
Article's Main Image

Lead asset Stendra® (avanafil) Looks to Build on $25 Million of 2019 Gross Sales

Disruptive pipeline opportunity with topical treatment for Peyronie's disease

Neurotrope Bioscience, Inc. will continue as a separately traded entity with its lead Bryostatin program treating neurodegeneration

Charles S. Ryan, J.D., Ph.D. named President and Chief Executive Officer of Petros

PR Newswire